Epigral Ltd
₹810.45
(-3.40%)
Sun, 05 Apr 2026, 11:21 pm
Epigral Ratios
| Particulars | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
| Price to earnings ratio | 0 | 0 | 0 | 16.01 | 11.09 | 23.25 | 22.42 |
| Price to book ratio | 0 | 0 | 0 | 5.57 | 3.67 | 3.63 | 4.30 |
| Price to sales ratio | 0 | 0 | 0 | 2.61 | 1.81 | 2.40 | 3.19 |
| Price to cash flow ratio | 0 | 0 | 0 | 17.14 | 6.92 | 13.98 | 21.39 |
| Enterprise value | 0 | 0 | 0 | 50.14B | 47.83B | 55.11B | 85.13B |
| Enterprise value to EBITDA ratio | 0 | 0 | 0 | 9.77 | 7.06 | 12.07 | 12.40 |
| Debt to equity ratio | 0.79 | 0.91 | 0.79 | 1.37 | 0.82 | 0.77 | 0.31 |
| Return on equity % | 0 | 21.14 | 15.88 | 35.85 | 39.36 | 16.86 | 22.65 |
Epigral Ltd Ratios
The Epigral Ltd Ratios page provides a complete fundamental analysis of Epigral Ltd using key valuation, profitability, and financial strength metrics. Investors tracking Epigral Ltd Ratios closely monitor D/E, EV, EV/EBITDA, P/B, P/CF, P/E, P/S, and ROE% to evaluate the company's financial performance and valuation trends over time.
Epigral Ltd (NSE: EPIGRAL, BSE: 543332) is currently trading at ₹810.45, with a market capitalization of ₹34.93B. As a major player in the Process industries sector and Chemicals: agricultural industry, Epigral Ltd remains a key stock for fundamental analysis using Epigral Ltd Ratios.
Epigral Ltd Ratios: Valuation Overview
Price to Earnings Ratio (P/E)
The Epigral Ltd P/E ratio currently stands at 22.42, making it one of the most tracked metrics in Epigral Ltd Ratios.
Historically, the Epigral Ltd P/E ratio has shown strong fluctuations:
- 2024: 22.42
- 2023: 23.25
- 2022: 11.09
- 2021: 16.01
- 2020: 0
The decline in Epigral Ltd P/E ratio suggests improving earnings relative to stock price.
Price to Book Ratio (P/B)
The Epigral Ltd P/B ratio reflects how the market values the company's net assets. Current P/B ratio is 4.30.
Historical P/B trend:
- 2024: 4.30
- 2023: 3.63
- 2022: 3.67
- 2021: 5.57
Epigral Ltd is trading at a premium to its book value, indicating strong market confidence.
Price to Sales Ratio (P/S)
The Epigral Ltd P/S ratio currently stands at 3.19, an important part of Epigral Ltd Ratios for revenue valuation.
Historical P/S ratio:
- 2024: 3.19
- 2023: 2.40
- 2022: 1.81
- 2021: 2.61
The rising Epigral Ltd P/S ratio indicates improved revenue valuation by investors.
Epigral Ltd Price to Cash Flow Ratio (P/CF)
The Epigral Ltd Price to Cash Flow Ratio is a key valuation metric that shows how much investors pay for each unit of cash flow. Current P/CF ratio is 21.39.
Historical Epigral Ltd Price to Cash Flow Ratio:
- 2024: 21.39
- 2023: 13.98
- 2022: 6.92
- 2021: 17.14
- 2020: 0
The rising Epigral Ltd Price to Cash Flow Ratio indicates premium valuation based on cash flow.
Epigral Ltd Enterprise Value Ratios
Enterprise Value (EV)
The Epigral Ltd EV currently stands at ₹85.13B, representing the total company valuation including debt.
Historical EV trend:
- 2024: 85.13B
- 2023: 55.11B
- 2022: 47.83B
- 2021: 50.14B
Epigral Ltd enterprise value shows long-term growth, reflecting expansion and market confidence.
EV/EBITDA Ratio
The Epigral Ltd EV/EBITDA ratio is currently 12.40, a key metric in Epigral Ltd Ratios to assess valuation relative to earnings.
Historical EV/EBITDA:
- 2024: 12.40
- 2023: 12.07
- 2022: 7.06
- 2021: 9.77
Higher Epigral Ltd EV/EBITDA suggests premium valuation.
Epigral Ltd Financial Strength Ratios
Debt to Equity Ratio (D/E)
The Epigral Ltd D/E ratio is currently 0.31, reflecting leverage and financial stability.
Historical D/E:
- 2024: 0.31
- 2023: 0.77
- 2022: 0.82
- 2021: 1.37
Epigral Ltd maintains a strong balance sheet with low debt levels.
Return on Equity (ROE %)
The Epigral Ltd ROE currently stands at 22.65%, showing profitability and capital efficiency.
Historical ROE:
- 2024: 22.65
- 2023: 16.86
- 2022: 39.36
- 2021: 35.85
Epigral Ltd demonstrates strong profitability and efficient capital utilization.
Epigral Ltd Ratios Analysis Summary
The Epigral Ltd Ratios page provides a comprehensive view of the company's valuation and financial performance. Key metrics such as P/E, P/B, P/S, P/CF, EV, EV/EBITDA, D/E, and ROE help investors understand whether Epigral Ltd stock is undervalued, fairly valued, or overvalued.
Tracking Epigral Ltd Ratios regularly helps investors make informed decisions based on valuation trends, financial stability, and long-term growth potential.
Open Your Free Demat Account Now!
Pocketful Fintech Capital Private Limited (CIN U65999DL2021PTC390548) | The SEBI Registration No. allotted to us is INZ000313732. NSE Member Code: 90326 | BSE Member Code: 6808 | MCX Member Code: 57120 DP | CDSL: 12099800